collaboration
Eisbach Bio, MD Anderson Partner to Identify Synthetic Lethal Drug Targets
The Munich-based company will combine its discovery and assay platforms with MD Anderson's therapeutics discovery expertise to identify and research cancer drugs.
BridgeBio, Amgen to Study SHP2 Inhibitor, Lumakras Combo in KRAS-Mutant Tumors
The nonexclusive collaboration further extends Amgen's ability to explore combination treatment approaches with sotorasib in a pan-tumor fashion.
Mission Bio, SequMed Ink Collaboration, Clinical Assay Codevelopment Agreement for China
The firms will work together on assays for cancer early detection, therapy selection, and disease monitoring, as well as on applications in reproductive genetics.
Novartis, BeiGene Ink Licensing Deal for TIGIT Inhibitor Ociperlimab
Novartis will pay BeiGene $300 million upfront for rights to develop and commercialize the agent, which BeiGene is studying with a checkpoint inhibitor in NSCLC and solid tumors.Â
BostonGene Partners with NEC to Offer Tumor Portrait Tests Internationally
NEC, an investor in BostonGene, will initially help provide Tumor Portrait to hospitals in Japan using its healthcare and life science network.